Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.
You may also be interested in...
FDA Hints At Additional Trials for Acusphere’s Imagify
Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.
FDA Hints At Additional Trials for Acusphere’s Imagify
Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.
CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
A2A-adenosine agonist could see FDA action by mid-March 2008.